Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.

J Clin Oncol 2019 Feb 30;37(4):286-295. Epub 2018 Oct 30.

1 Memorial Sloan Kettering Cancer Center, New York, NY.

Purpose: Microsatellite instability (MSI) and/or mismatch repair deficiency (MMR-D) testing has traditionally been performed in patients with colorectal (CRC) and endometrial cancer (EC) to screen for Lynch syndrome (LS)-associated cancer predisposition. The recent success of immunotherapy in high-frequency MSI (MSI-H) and/or MMR-D tumors now supports testing for MSI in all advanced solid tumors. The extent to which LS accounts for MSI-H across heterogeneous tumor types is unknown. Here, we establish the prevalence of LS across solid tumors according to MSI status.

Methods: MSI status was determined using targeted next-generation sequencing, with tumors classified as MSI-H, MSI-indeterminate, or microsatellite-stable. Matched germline DNA was analyzed for mutations in LS-associated mismatch repair genes ( MLH1, MSH2, MSH6, PMS2, EPCAM). In patients with LS with MSI-H/I tumors, immunohistochemical staining for MMR-D was assessed.

Results: Among 15,045 unique patients (more than 50 cancer types), LS was identified in 16.3% (53 of 326), 1.9% (13 of 699), and 0.3% (37 of 14,020) of patients with MSI-H, MSI-indeterminate, and microsatellite-stable tumors, respectively ( P < .001). Among patients with LS with MSI-H/I tumors, 50% (33 of 66) had tumors other than CRC/EC, including urothelial, prostate, pancreas, adrenocortical, small bowel, sarcoma, mesothelioma, melanoma, gastric, and germ cell tumors. In these patients with non-CRC/EC tumors, 45% (15 of 33) did not meet LS genetic testing criteria on the basis of personal/family history. Immunohistochemical staining of LS-positive MSI-H/I tumors demonstrated MMR-D in 98.2% (56 of 57) of available cases.

Conclusion: MSI-H/MMR-D is predictive of LS across a much broader tumor spectrum than currently appreciated. Given implications for cancer surveillance and prevention measures in affected families, these data support germline genetic assessment for LS for patients with an MSI-H/MMR-D tumor, regardless of cancer type or family cancer history.

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00283
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553803PMC
February 2019
84 Reads
18.430 Impact Factor

Publication Analysis

Top Keywords

msi-h/i tumors
12
tumors
11
immunohistochemical staining
8
solid tumors
8
msi-h msi-indeterminate
8
msi-indeterminate microsatellite-stable
8
lynch syndrome
8
patients msi-h/i
8
mismatch repair
8
microsatellite instability
8
patients
7
cancer
6
msi
5
prevalence solid
4
microsatellite-stable matched
4
tumors patients
4
establish prevalence
4
patients non-crc/ec
4
cell tumors
4
personal/family history
4

Similar Publications